Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption

Mol Ther. 2025 Jan 8;33(1):417-418. doi: 10.1016/j.ymthe.2024.11.031. Epub 2024 Nov 27.
No abstract available

Publication types

  • Published Erratum